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Abstract: The present study was undertaken to develop a rat model for monitoring the early 
development of breast cancer. Twelve female rats were divided into two groups of six rats 
that were either treated with N-methyl-N-nitrosourea to induce breast cancer or with bacterial 
lipopolysaccharide to induce inflammation. Serum samples taken from the rats prior to the 
treatment were used as controls. By the 14th week, presence of the tumor was detectable by 
contrast enhanced magnetic resonance imaging and confirmed by histopathology. When the 
serum proteins of the rats were examined by 2-dimensional electrophoresis (2-DE), no 
difference could be detected in the profiles of all proteins before and 18 weeks after 
administration of N-methyl-N-nitrosourea. However, higher expression of alpha-1B 
glycoprotein was detectable by 2-DE in serum samples of rats at the 18th week post-treatment 
with lipopolysaccharide. 
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1. Introduction  
Breast cancer is one of the most common cancers in the world. It accounts for 10.9% of all cancers, 
with a reported incidence of about 1.38 million cases in 2008 [1]. Detection of breast cancer is heavily 
dependent on imaging techniques including mammograms, ultrasound, different types of scans and 
magnetic resonance imaging (MRI). The use of biomarkers for early diagnosis of breast cancer is not 
yet considered reliable. As symptoms of breast cancer widely vary and may be similar to  
non-cancerous conditions, like an infection or a cyst, diagnosis is typically made at the late stages of 
the disease. 
The potential of MRI for early diagnosis of breast cancer is now recognized. The T2-weighted MRI 
has been reported to accurately detect high signals from rat breast tumors. Out of 18 tumors of less 
than 1 mm in sizes, 17 were detected without the use of contrast [2]. Dynamic contrast enhanced-MRI 
has also been shown to improve early detection of cancer [3–5]. A study has reported that the tumor 
microvessels may be recognized using the macromolecular particulate MRI contrast agent for 
enhancement of the reticuloendothelial system [6]. Therefore, the method may be more suitable for 
detection of small malignant breast tissues. In fact, the American Cancer Society has recommended the 
use of contrast enhanced MRI for screening of women at high risk for developing breast cancer.  
Another possible approach for early breast cancer detection is by profiling changes in the  
acute-phase reactant proteins (APRPs) in serum. The acute-phase response is an animal’s immediate 
reaction to an infection or other types of immunological stress [7]. Changes in the concentrations of 
serum or plasma APRPs are one of the responses in an acute-phase reaction to an injury/trauma, 
inflammation, infection or diseases including cancer. We have been examining the APRP patterns of 
sera from cancer patients to evaluate their applicability for the diagnosis of cancer. By using the  
gel-based proteomics approach, alterations in the APRPs of sera from distinct cancers have been 
documented [8–11]. For example, sera from breast cancer patients showed an increased expression of 
three proteins and decreased expression of two proteins. Our findings are in agreement with those of 
many others [12–15], suggesting that the different patterns of APRP alteration may be used as protein 
signatures for diagnostic [16] as well as prognostic purposes [17]. Nevertheless, one deficiency of the 
previous studies of the APRP levels in cancer patients was that the subjects may have varied in terms 
of their tumor load, stages of cancer, age groups, etc. This was quite unavoidable since the studies 
were reliant on the limited availability of serum samples from newly-diagnosed and untreated patients 
who presented themselves at the hospital. Therefore, in order to evaluate the potential for using serum 
APRPs for early diagnosis of cancer an animal model will be beneficial. 
In the present study, we used a rat model to investigate the early development of breast cancer using 
contrast enhanced MRI and determined whether changes in serum APRPs were notable in the very 
early stages of development of breast tumors in rats. Presence of breast tumor was confirmed by 
histopathological examination of the rat mammary tissues. Further, we included controls to distinguish 
changes that were due to inflammation per se as opposed to malignancy. Serum samples from rats that 
were chemically induced with breast cancer, as well as those induced with inflammation, were 
subjected to 2-dimensional electrophoresis (2-DE) and compared to the 2-DE profiles of control rat 
sera obtained prior to the chemical treatments.  
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2. Results  
2.1. Histological Staining of Rat Mammary Sections 
In contrast to the normal rat mammary tissues, the abdominal-inguinal and contralateral mammary 
glands of rats induced with breast cancer showed alteration in their tissue structures (Figure 1), which 
in comparison with the report by Murray et al. [18], was similar to a pregnant or lactating mammary 
gland phenotype. A number of alterations were observed in the morphology of breast tissues in the 
group of rats injected with N-methyl-N-nitrosourea (NMU). An increase in the number of acini, further 
epithelial differentiation with secretory material, ductal carcinoma in situ (DCIS), hyperplastic ducts 
containing more than three layers of epithelial cells and large dilated ducts in a lobular configuration 
were also noticed. There were occasional areas showing benign proliferation of the ducts and crowding 
of acini. In one of the rat samples, scattered atypical cells with hyperchromatic nuclei (an indication of 
early stromal invasion), in combination with DCIS was noted. This is an indication of early invasive 
cancerous change although there was no significant alteration that was noticed in the stroma.  
Figure 1. Mammary tissue histology and pathology snapshots of (a) normal appearance 
without any evidence of glandular proliferation of a normal rat, (b) lobular architecture of 
breast acini in a rat treated with bacterial lipopolysaccharide (LPS), and (c) ductal 
carcinoma in situ (DCIS) changes noticed in many glands (shown by arrows) in a rat 
treated with N-methyl-N-nitrosourea (NMU).  
 
2.2. MRI Analysis 
Sagittal T1 Fat Sat contrast enhanced image of the rat was successfully scanned using gadolinium 
as a contrast agent at 14 weeks after injection of NMU (Figure 2). There was marked enhancement of 
the upper set of the mammary glands in the post gadolinium images measuring 2 mm in the long axis 
but no noticeable enhancement in the lower mammary glands.  
(a) (b) (c) 
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Figure 2. Sagittal T1 Fat Sat magnetic resonance imaging (MRI) contrast image of a rat at 
14 weeks after injection of a cancerous agent. There was marked enhancement of the upper 
set of mammary glands: 5.2 mm in length in this rat (between small arrows) but no 
enhancement of the lower set of mammary glands.  
 
2.3. 2-DE Serum Protein Profiles 
When proteins from control rat serum samples were separated by 2-DE and stained with silver, 
complex protein profiles containing hundreds of spots were obtained. Serum samples of each treated 
rat group were subsequently resolved using the same technique. Figure 3 shows the representative 
serum protein profiles of normal female control rats and rats treated with NMU and LPS, respectively. 
Identities of the 2-DE resolved proteins from serum isolated in the first (control samples) and the final 
(rats assumed to have cancer/inflammation) weeks were initially established by visual comparison of 
the 2-DE gels with previously published protein maps obtained from rat sera [19]. Identities of the 
serum proteins were then confirmed by mass spectrometry and database search (Table 1).  
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Figure 3. Typical 2-DE profiles of rat serum samples. Panels show typical profiles of 
serum proteins of (a) LPS-treated rats, (b) rats treated with NMU and their respective 
control sera (c) and (d). Protein spot identities and the acronyms used are in accordance to 
Table 1. Acid sides of gels are to the left and molecular mass declines from the top. 
 
Table 1. Tandem mass spectrometric identification of spot clusters from rat serum 2-DE profiles. 
APRP# 
Accession Number 
(Swiss-Prot) 
Theoretical 
Mass 
Mascot 
Score 
Theoretical 
pI 
No of 
Peptide Hits 
Sequence 
Coverage (%) 
ALB (serum albumin) P02770 68686 739 6.46 12 27 
AHS (α2-HS glycoprotein) P24090 37958 263 6.05 4 22 
ABG (α1B-glycoprotein) Q9EPH1 56443 272 6.89 7 14 
KNG1 (T-kininogen) P01048 47745 296 6.08 6 20 
KBP (kallikrein-binding protein) P05545 46532 327 5.31 8 22 
SPI-3 (serine protease inhibitor) P09006 46622 384 5.33 7 21 
APO (apolipoprotein A-IV) P02651 44429 770 5.12 15 45 
AMG (α1-macroglobulin) Q63041 167019 643 6.46 10 6 
HAP (haptoglobin) P06866 38539 508 6.10 12 32 
AAT (α1-antitrypsin) P17475 46107 720 5.70 13 34 
HPX (hemopexin) P20059 51318 498 7.58 9 19 
FBP (fetuin-B precursor) Q9QX79 41506 451 6.71 9 40 
KNG2 (T-kininogen) P01048 47745 424 6.08 8 18 
#APRP spot ID are as in Figure 1. 
 
ALB 
KNG1 
KBP 
HPX 
(b) (a) 
(c) (d) 
ALB 
ALB 
HAP 
AMG APO 
FBP 
AHS 
AAT SPI-3 
KNG2 
ABG 
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2.4. Analysis of Spot Volumes 
Volume analysis of the 13 spot clusters within and between the different groups of rat serum 
samples demonstrated comparable expression of almost all the highly abundant proteins detected. For 
most protein clusters, comparable expression was detected between the groups of rats treated with 
NMU compared with those of the rat normal serum samples (Figure 4a). The spot clusters of albumin 
and fetuin-B precursor were apparently not conducive to the analysis. In contrast, the group of rats 
injected with LPS showed significant variation in the expression of alpha-1B glycoprotein (Figure 4b). 
Figure 4. Mean percentage of volume contribution of rat serum APRPs. Panels 
demonstrate values for rats induced with (a) breast cancer and (b) inflammation, versus 
their respective control sera. Analysis was determined using the ImageMaster
TM
 2D 
Platinum Software 7.0. A p value of less than 0.05 was considered significant (*).  
 
 
 
 
3. Discussion  
By 18 weeks post injection of NMU, none of the rats in the breast cancer group demonstrated any 
signs or symptoms of the disease on general observation or palpation, although histopathological 
examination of the mammary gland tissues showed an indication of early invasive cancerous change. 
This apparent contradiction may be explained to a certain extent by differing reports in the literature. 
For example, one report indicated a mean incidence of one cancer per rat at the 16th week after 
carcinogen administration [20], whereas Roomi et al. (2005) observed that the probability of 
generating palpable tumors in rats is higher at more than 20 weeks subsequent to NMU injections [21].  
(a) 
NMU-treated 
(b) 
LPS-treated 
* 
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Despite the lack of physical evidences, marked enhancement of tumor in the mammary gland of rats 
treated with NMU was successfully detected by contrast enhanced MRI. Most previous imaging 
studies of the mouse model focused on large mammary tumors and were performed in dedicated 
animal MRI units of 4.7 Tesla to 7 Tesla. This study showed the possibility of detecting very small 
amounts of breast cancer tissues using standard clinical 3 Tesla MRI equipment. In addition, the study 
was performed with just a basic custom made mold to house the rat, a pre-estimated dosage of contrast 
according to the weight of the rat and imaging within a standard knee coil. However, more cases that 
correlate to the biopsies need to be performed.  
On the contrary, serum proteomic profiles of highly abundant proteins from the control sera and 
those obtained from sera of rats that were induced with breast cancer at the 18th week after injections 
with NMU did not show significant differences in the expression of any of the proteins analyzed. This 
suggests that APRPs at the very early stages of tumor development are not detectable by current 
proteomic approaches, even if they were present. Apparently, the rat tumor has to reach some critical 
mass before significant quantities of APRPs enter the circulation.  
In contrast to the rats that were chemically induced with breast cancer, those treated with bacterial 
LPS showed significant up-regulated expression of alpha-1B glycoprotein at the 18th week after 
receiving the injections. The expression of other APRPs was not altered. Alpha-1B glycoprotein, a 
serum protein of unknown function, appeared to be part of the first line of APRPs that was induced in 
response to inflammation. The altered expression of serum alpha-1B glycoprotein in the rats treated 
with LPS forms an early evidence for the difference in the acute-phase response to inflammation from 
that which was induced by breast cancer.  
When taken together, the data of our study demonstrated the possibility of contrast enhanced MRI 
recognition of a tumor at an early stage of breast cancer when the APRP changes in the rat sera were 
not able to illustrate clear differences.  
4. Experimental Section 
4.1. Rat Serum Samples 
Twelve, two month old, inbred and virgin female Sprague-Dawley rats were used. Each rat was 
individually caged at the animal quarters at 23–25 °C and 35–55% humidity, with normal light-dark 
cycle. Regular chow pellets and normal tap water were supplied ad libitum. The first bleeding was 
performed five days prior to treatment with chemicals and the serum samples obtained were used as 
normal controls. Blood was taken from the tail vein using 23 gauge butterfly needles and serum 
samples were stored at –80 °C. The rats were sacrificed 18 weeks after the first injection of chemicals 
and their breast tissues were dissected. All experimental procedures were approved by the Animal 
Research Committee of the University of Malaya Medical Centre in accordance with the guide for care 
and use of laboratory animals.  
4.2. Chemical Treatment 
N-Methyl-N-nitrosourea (NMU) and lipopolysaccharide (LPS) from E. coli were purchased from 
Sigma Aldrich Chemical Company (St Louis, MO, U.S.). Six rats received a single intraperitoneal 
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dose of 50 mg/kg NMU for inducement of breast cancer while the rest received 0.06 mg/kg LPS to 
initiate inflammation. The NMU solutions were used within 15 min of preparation.  
4.3. Histological Staining 
The abdominal-inguinal and contralateral mammary glands were collected from euthanized rats at 
18 weeks after the NMU injections. The mammary glands were fixed in 10% formalin overnight, 
processed and embedded into paraffin blocks. Sections were cut at 4 µm thickness and stained with 
Hematoxylin (Biostain Ready Reagents Ltd, Cheshire, UK) and Eosin (Richard-Allan Scientific, 
Kalamazoo, MI, U.S.) on frosted slides. Breast tissues were examined under a light microscope to 
observe for microscopic cancerous and precancerous lesions and confirmed by an experienced 
histopathologist. 
4.4. Contrast Enhanced MRI 
Rats at the 14th week after NMU injections were anesthetized by intramuscular injection with 
ketamine (80–110 mg/kg) and xylazine (12 mg/kg) (Troy Laboratories Australia Pty Ltd, Sydney, 
Australia), to prevent movement prior to MRI. A 24 gauge angiocatheter was placed in the tail vein 
and injected with heparin-saline to prevent blockage. An IV contrast agent, gadopentetate 
dimeglumine (Magnevist―469 mg/mL; Bayer Schering Pharma AG, Berlin, Germany), diluted with 
heparinized sterile saline solution at 0.2 mL/kg, was injected at the contrast phase of the MRI. The rats 
were placed on a polystyrene mold that was inserted into the knee coil of a standard clinical 3 Tesla 
magnet GE Healthcare MRI equipment. A scout image was taken for anatomical references to ensure 
that the upper and lower mammary glands were covered. T1, T2, and post gadolinium fat sat T1 
images were acquired in different planes (see Table 2 for parameter settings).  
Table 2. Parameters used for contrast enhanced MRI. Scanner type: 3.0T Signa Hdxt. Type 
of head coil: HD T/R knee/foot coil by INVIVO.  
Parameters AX FSE PD AX T1 SE FAT SAT AX T1 SE FAT SAT + 
CONTRAST 
SAG T1 FAT SAT + 
CONTRAST 
BANDWITH: 62.5 11.9 11.9 11.9 
FOV  8 × 8 8 × 8 8 × 8 8 × 8 
FREQ: 512 × 224 192 × 160 192 × 160 192 × 160 
IMAGING OPTIONS  FAST, NPW, TRF NPW, ZIP512, StFCl NPW, ZIP512, StFCl NPW, ZIP512, StFCl 
MODE: 2D 2D 2D 2D 
NEX: 1 2 2 1 
PULSE  SEQ:FSE-XL SEQ:FSE-XL FSE-XL FSE-XL 
SHIM: AUTO AUTO AUTO AUTO 
SLICE THICK: 2 2 2 3 
SPACING:  0 0 0 0 
TE: 33.5 13 13 13 
TR:  7660 900 900 740 
Although a 30-min sedation for MRI was planned for the rats, scans had to be done within 20 min 
as some of the rodents developed significant bradycardia and extreme low blood pressure after 15 min. 
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This may be partly due to hypothermia because of the cold MRI room, which may be reduced by using 
a hot air blower that was directed at the knee coil [22,23]. In a few of the sedated rats, imaging had to 
be abandoned as contrast was not able to be administered due to constriction of vessels and decreased 
peripheral blood circulation, especially at the sites for IV contrast administration in the tail vein.  
4.5. 2-DE and Mass Spectrometry 
2-DE and mass spectrometry using the 4800 Plus MALDI TOF/TOF analyzer (Applied 
Biosystems/MDS Sciex, Toronto, Canada) were performed as previously described [8,24]. Protein 
spots were identified using the MASCOT search engine (Matrix Science Ltd, London, U.K.; release 
version 2.1.0) against rattus entries in the Swiss-Prot database (Last update October 23, 2008, 
containing 261513 sequences). The following variables were set as search parameters: trypsin was 
used; up to one missed cleavage was allowed; variable modifications included were 
carbamidomethylation of cysteine and oxidation of methionine; the mass tolerance for MS precursor 
ion and MS/MS fragment ion were 100 ppm and 0.2 Da, respectively; and only monoisotopic masses 
were included in the search. 
4.6. Image and Statistical Analyses 
The GE ImageMaster
TM
 2D Platinum Software version 7 was used to analyze expression of proteins 
in the 2-DE profiles. Percentage volume contribution of protein spots, which refers to the spot volume 
of a protein expressed as a percentage of the total spot volume of all detected serum proteins, was 
calculated to detect proteins that were differentially expressed in the rat serum. The ANOVA statistical 
test was used to analyze the protein spot differences between the profiles. A p value of less than 0.05 
was considered significant. 
5. Conclusions 
Contrast enhanced MRI using gadolinium as the contrast agent appeared to have the capability to 
detect the NMU-induced tumor at 14 weeks of development. However, the serum APRP profiles of 
rats before and 18 weeks subsequent to NMU injections did not show any significant difference, 
although pathological examination of the breast tissues of the animals demonstrated obvious evidence 
of early tumor development.  
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